Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sigrid Therapeutics AB has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners. Both pending actions are concentrated within 1 distinct art unit.
GEMBEH, SHIRLEY V is the busiest examiner for the company with 1 pending action. The focus on 1 distinct art unit suggests a specific technical area for the portfolio. However, the presence of 2 distinct examiners means the company must navigate different individual perspectives within that single art unit.
With 2 pending office actions and 2 distinct examiners, there is no examiner overlap. This requires the company to tailor its prosecution strategy to different individuals, even though they are both working within the same technical group. The 1 action per examiner ensures that each case receives an independent review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| TRAN, SUSAN T | 1 | 63.0% | +34.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19105140 | DIETARY SUPPLEMENTS COMPRISING SILICA PARTICLES | GEMBEH, SHIRLEY V | — |
| 18835391 | ORAL CARE COMPOSITION COMPRISING POROUS SILICA PARTICLES | TRAN, SUSAN T | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19105140 | DIETARY SUPPLEMENTS COMPRISING SILICA PARTICLES | GEMBEH, SHIRLEY V | 1615 | §102§103DP | Non-Final OA | — | Pending | Feb 20, 2025 |
| 18835391 | ORAL CARE COMPOSITION COMPRISING POROUS SILICA PARTICLES | TRAN, SUSAN T | 1615 | §102 | Non-Final OA | — | Pending | Aug 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSigrid Therapeutics AB has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Shirley V Gembeh has the most, with 1 of Sigrid Therapeutics AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
